Ligand id: 9640

Name: rontalizumab

Compound class Antibody
International Nonproprietary Names
INN number INN
9114 rontalizumab
9F3v13 | RhuMAB IFNalpha | rhuMAb interferon-α
Rontalizumab is a humanized monoclonal antibody targeting interferon alpha (IFNα) that has immunomodulatory potential. It was humanized from a mouse monoclonal as described in [2], and peptide sequences of the antibody (identified as humanized 9F3v13) are claimed in Genentech patent US7582445 [1].
Rontalizumab is functionally similar to sifalimumab. Development of both of these anti-IFNα agents has been discontinued. Compare these with anifrolumab, which targets the type I interferon receptor (IFNAR1) rather than the ligand itself, and which has progressed to Phase 3 clinical trial.
A 3D X-ray structure of rontalizumab's Fab domain bound to IFNα2 has been published (PDB identifier 4Z5R) [5].
Database Links
Specialist databases
IMGT/mAb-DB 327
Other databases
GtoPdb PubChem SID 340590270
Search PubMed clinical trials rontalizumab
Search PubMed titles rontalizumab
Search PubMed titles/abstracts rontalizumab